Growth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational study.
Juan Pedro López-SigueroMaria J Martínez-AedoJose Antonio Bermúdez de la VegaJordi Bosch MuñozAlfonso María Lechuga-SanchoTriana Villalobosnull nullPublished in: Clinical endocrinology (2021)
HOMA-IR values increased significantly in SGA-children during the first year of GH-treatment, remained stable and were within normal ranges in all cases. Our 10-year data suggests that long-term GH treatment does not promote IR and is well-tolerated, safe and effective.
Keyphrases
- growth hormone
- insulin resistance
- end stage renal disease
- metabolic syndrome
- body mass index
- type diabetes
- chronic kidney disease
- adipose tissue
- ejection fraction
- birth weight
- skeletal muscle
- newly diagnosed
- peritoneal dialysis
- signaling pathway
- high fat diet
- machine learning
- cell proliferation
- physical activity
- prognostic factors
- patient reported outcomes
- data analysis
- weight gain